Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 6 records in total 6
    records per page




    Seroprevalence SERO of anti-SARS-CoV-2 IgG antibody SERO in hospitalized patients in a tertiary referral center in North India

    Authors: Animesh Ray; Komal Singh; Souvick Chattopadhyay; Farha Mehdi; Gaurav Batra; Aakansha Gupta; Ayush Agarwal; Bhavesh M; Shubham Sahni; Chaithra R; Shubham Agarwal; Chitrakshi Nagpal; Gagantej B H; Umang Arora; Kartikeya Kumar Sharma; Ranveer Singh Jadon; Ashish Datt Upadhyay; Neeraj Nischal; Naval K Vikram; Manish Soneja; R M Pandey; Naveet Wig; Alessandra C. Sanchez; Haifa L. Gaza; Geraldine M. Arevalo; Coleen M. Pangilinan; Shaira A. Acosta; Melanie V. Salinas; Brian E. Schwem; Angelo D. Dela Tonga; Ma. Jowina H. Galarion; Nina Theresa P. Dungca; Stessi G. Geganzo; Neil Andrew D. Bascos; Eva Maria Cutiongco-de la Paz; Cynthia P. Saloma; Alberto L Garcia-Basteiro

    doi:10.1101/2020.08.22.20179937 Date: 2020-08-25 Source: medRxiv

    Background: Seroprevalence SERO of IgG antibodies SERO against SARS-CoV-2 is an important tool to estimate the true extent of infection MESHD in a population. However, seroprevalence SERO studies have been scarce in South East Asia including India, which, as of now, carries the third largest burden of confirmed cases TRANS in the world. The present study aimed to estimate the seroprevalence SERO of the anti-SARS-CoV-2 IgG antibody SERO among hospitalized patients at one of the largest government hospital in India. Method: This cross-sectional study, conducted at a tertiary care hospital in North India, recruited consecutive patients who were negative for SARS-CoV-2 by RT-PCR or CB-NAAT. Anti-SARS-CoV-2 IgG antibody SERO levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum samples SERO by the ELISA SERO method. Results: A total of 212 hospitalized patients were recruited in the study with mean age TRANS (+/-SD) of 41.2 (+/-15.4) years and 55% male TRANS population. Positive serology against SARS CoV-2 was detected in 19.8% patients(95% CI 14.7-25.8). Residency in Delhi conferred a higher frequency of seropositivity 26.5% (95% CI 19.3-34.7) as compared to that of other states 8% (95% CI 3.0-16.4) with p-value 0.001. No particular age groups TRANS or socio-economic strata showed a higher proportion of seropositivity. Conclusion: Around, one-fifth of hospitalized patients, who were not diagnosed with COVID-19 before, demonstrated seropositivity against SARS-CoV-2. While there was no significant difference in the different age groups TRANS and socio-economic classes; residence in Delhi was associated with increased risk (relative risk of 3.62, 95% CI 1.59-8.21) Key Words: SARS-CoV-2 IgG Antibody SERO, Seroprevalence SERO, Hospitalized patient, COVID-19

    A Comprehensive Evaluation of Early Predictors of Disease MESHD Progression in Patients with COVID-19: A Case Control Study

    Authors: Qiang Tang; Yanwei Liu; Yingfeng Fu; Ziyang Di; Kailiang Xu; Bo Tang; Hui Wu; Maojun Di

    doi:10.21203/rs.3.rs-50527/v1 Date: 2020-07-29 Source: ResearchSquare

    Background: The 2019 coronavirus disease MESHD (COVID-19) has become an unprecedented public health crisis with nearly 16 million confirmed cases TRANS and 630,000 deaths worldwide. Methods: We retrospectively investigated the demographic, clinical, laboratory, radiological and treatment data of COVID-19 patients consecutively enrolled from January 18 to May 15, 2020, in Taihe and Jinzhou central hospital. Results: Of all 197 patients, the median age TRANS was 66.5 years (IQR 7-76), and 120 (60.9%) patients were males TRANS. We identified 88 (44.7%) of 197 COVID-19 patients as the disease progression (aggravation) cases. The aggravation cases tend to have more medical comorbidity: hypertension HP hypertension MESHD (34.1%), diabetes MESHD (30.7%), and presented with dyspnea HP dyspnea MESHD (34.1%), neutrophilia HP (60.2%), and lymphocytopenia MESHD (73.9%), compared with those without. And the patients with disease progression showed significantly higher level of Fibrinogen (Fbg), D-dimer, IL-6, C-reactive protein (CRP), procalcitonin (PCT), and serum SERO ferritin, and were more prone to develop organ damage in the liver, kidney, and heart (P<0.05). Multivariable regression showed that advanced age TRANS, comorbidities, lymphopenia HP lymphopenia MESHD, and elevated level of Fbg, lactate dehydrogenase (LDH), Cardiac troponin (CTnI), IL-6, serum SERO ferritin were the significant predictors of disease progression. Further, we investigated antibody SERO responses to SARS-CoV-2 and found that the levels of IgM and IgG were significantly higher in the disease progression cases compared to non-progression cases from 3 weeks after symptom onset TRANS. In addition, the disease progression group tended to peak later and has a more vigorous IgM/IgG response against SARS-CoV-2. Further, we performed Kaplan-Meier analysis and found that 61.6% of patients had not experienced ICU transfer or survival from hospital within 25 days from admission.Conclusions: Investigating the potential factors of advanced age TRANS, comorbidities and elevated level of IL-6, serum SERO ferritin and Kaplan-Meier analysis enables early identification and management of patients with poor prognosis. Detection of the dynamic antibody SERO may offer vital clinical information during the course of SARS-CoV-2 and provide prognostic value for patients infection MESHD.  

    Antibody Testing SERO Documents the Silent Spread of SARS-CoV-2in New York Prior to the First Reported Case

    Authors: Kathrine Meyers; Lihong Liu; Wen-Hsuan Lin; Yang Luo; Michael Yin; Yumeng Wu; Sandeep Wontakal; Alex Rai; Francesca La Carpia; Sebastian Fernando; Mitra Dowlatshahi; Elad Elkayam; Ankur Garg; Leemor Joshua-Tor; John Wolk; Barbara Alpert; Marie-Laure Romney; Brianna Costabile; Edoardo Gelardi; Francesca Vallese; Oliver Clarke; Filippo Mancia; Anne-Catrin Uhlemann; Magdalena Sobieszczyk; Alan Perelson; Yaoxing Huang; Eldad Hod; David Ho

    doi:10.21203/rs.3.rs-39880/v1 Date: 2020-07-02 Source: ResearchSquare

    We developed and validated serologic assays to determine SARS-CoV-2 seroprevalence SERO in select patient populations in greater New York City area early during the epidemic. We tested “discarded” serum samples SERO from February 24 to March 29 for antibodies SERO against SARS-CoV-2 spike trimer and nucleocapsid protein. Using known durations for antibody SERO development, incubation period TRANS, serial interval TRANS, and reproductive ratio for this pandemic, we determined that introduction of SARS-CoV-2 into New York likely occurred between January 23 and February 4, 2020. SARS-CoV-2 spread silently for 4–5 weeks before the first community acquired infection MESHD was reported. A novel coronavirus emerged in December 2019 in Wuhan, China1,2 and devasted Hubei Province in early 2020 before spreading to every province within China and nearly every country in the world3. This pathogen, now termed severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has caused a global pandemic, with ~ 10 million cases and over 500,000 deaths MESHD reported through June 30, 20203. The first case of SARS-CoV-2 infection MESHD in the United States was identified on January 19, 2020 in a man who returned to the State of Washington from Wuhan4. In the ensuing months, the U.S. has become a hotspot of the pandemic, presently accounting for almost one third of the total caseload and over one fourth of the deaths3. The first confirmed case TRANS in New York was reported on March 1 in a traveler recently returned from Iran. The first community-acquired SARS-CoV-2 infection MESHD was diagnosed on March 3 in a 50-year-old male TRANS who lived in New Rochelle and worked in New York City (https://www1.nyc.gov/site/doh/covid/covid-19-data-archive.page.) In the ensuing 18 weeks, New York City has suffered a peak daily infection number of ~ 4,500 (Fig. 1a) and a cumulative caseload of ~ 400,000 to date. The time period when SARS-CoV-2 gained entry into this epicenter of the pandemic remains unclear.

    Prevalence SERO of SARS-CoV-2 infection MESHD in the Luxembourgish population: the CON-VINCE study.

    Authors: Chantal J. Snoeck; Michel Vaillant; Tamir Abdelrahman; Venkata P. Satagopam; Jonathan D. Turner; Katy Beaumont; Clarissa P. C. Gomes; Joelle Veronique Fritz; Valerie E. Schröder; Anne Kaysen; Lukas Pavelka; Lara Stute; Guilherme Ramos Meyers; Laure Pauly; Maxime Hansen; Claire Pauly; Gloria A. Aguayo; Magali Perquin; Anne-Marie Hanff; Soumyabrata Ghosh; Manon Gantenbein; Laetitia Huiart; Markus Ollert; Rejko Krüger

    doi:10.1101/2020.05.11.20092916 Date: 2020-05-18 Source: medRxiv

    BACKGROUND: After the World Health Organization declared the outbreak of coronavirus disease MESHD to be a public health emergency of international concern on January 30, 2020, the first SARS-CoV-2 infection MESHD was detected in Luxembourg on February 29, 2020. Representative population-based data, including asymptomatic TRANS individuals for assessing the viral spread and immune response were, however, lacking worldwide. METHODS: Using a panel-based method, we implemented a representative sample of the Luxembourgish population based on age TRANS, gender TRANS and residency for testing for SARS-CoV-2 infection MESHD and antibody SERO status in order to define prevalence SERO irrespective of clinical symptoms. Participants were contacted via email to fill an online questionnaire before biosampling at local laboratories. All participants provided information related to clinical symptoms, epidemiology, socioeconomic and psychological assessments and underwent biosampling, rRT-PCR testing and serology for SARS-CoV-2. RESULTS: We included a total of 1862 individuals in our representative sample of the general Luxembourgish population. Of these, 5 individuals had a current positive result for infection MESHD with SARS-CoV-2 based on rRT-PCR. Four of these individuals were oligosymptomatic and one was asymptomatic TRANS. Overall we found a positive IgG antibody SERO status in 35 individuals (1.97%), of which 11 reported to be tested positive by rRT-PCR for SARS-CoV-2 previously and showed in addition their IgG positive status also a positive status for IgA. Our data indicate a prevalence SERO of 0.3% for active SARS-CoV-2 infection MESHD and an infection rate of 2.15% in the Luxembourgish population between 18 and 79 years of age TRANS. CONCLUSIONS: Luxembourgish residents show a low rate of acute infections MESHD after 7 weeks of confinement and present with an antibody SERO profile indicative of a more recent immune response to SARS-CoV-2. All infected individuals were oligo- or asymptomatic TRANS. Bi-weekly follow-up visits over the next 2 months will inform about the viral spread by a- and oligosymptomatic carriers TRANS and the individual changes in the immune profile.

    The multicenter study of Chest HRCT imaging characteristics of 2019 Novel Coronavirus (COVID-19) Pneumonia HP

    Authors: Zhehao Lyu; Meiji Ren; Lian-Ming Wu; Yuxin Yang; Yi-Bo Lu; Li Li; Xiaoming Gong; Zhiyan Lu; Hongjun Li

    doi:10.21203/rs.3.rs-20837/v1 Date: 2020-04-02 Source: ResearchSquare

    Background: In December 2019, a cluster of patients with pneumonia HP pneumonia MESHD of unknown cause was linked to a seafood wholesale market in Wuhan, China. A novel coronavirus was detected, capable of infecting humans, on 6 January 2020 and termed COVID-19. By 16 February 2020, there were 51857 confirmed cases TRANS with 2019-nCoV (COVID-19) pneumonia HP pneumonia MESHD in 25 countries. COVID-19 can also lead to acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD).Methods: 149 patients with 2019 Novel Coronavirus (COVID-19) pneumonia HP pneumonia MESHD(68 males TRANS, 81 females TRANS, ages TRANS 1-89)from 6 research centers in China were diagnosed with positive 2019 Novel Coronavirus(COVID-19)nucleic acids antibodies SERO. And their high-resolution computed tomography(HRCT) imaging datas were evaluated.Results: 136/149(91.3%)patients had a clear history of exposure to Wuhan. Fever HP Fever MESHD (122/149, 81.9%)and cough HP(83/149, 55.7%)were the most common symptoms. The main imaging characteristics within 4 days of onset included 30(20.13%) cases of pure ground glass opacities (P<0.05), 38(25.50%) cases of GGO with reticulation(P<0.01), 12(8.05%) cases of consolidation(P<0.01). In the 5-8 days group, the main imaging features included 71(47.65%) cases of pGGO(P<0.05), 69(46.31%) cases of GGO with reticulation(P<0.01). In the 9-12 days group, the main feature was 85(57.04%) cases with GGO with reticulation(P<0.01). In the group of 13-16 days group, the main imaging characteristics included 48(32.21%) cases of GGO with reticulation(P < 0.01), 34(22.82%) cases of consolidation(P<0.01).Conclusion: Patients infected with COVID-19 pneumonia HP pneumonia MESHD show more chest CT characteristics within 5-8 days after the onset of disease. The main manifestations included pGGO, GGO with reticulation, consolidation and GGO with consolidation.

    Precautions are Needed for COVID-19 Patients with Coinfection of Common Respiratory Pathogens

    Authors: Quansheng Xing; Guoju Li; Yuhan Xing; Ting Chen; Wenjie Li; Wei Ni; Kai Deng; Ruqin Gao; Changzheng Chen; Yang Gao; Qiang Li; Guiling Yu; Jianning Tong; Wei Li; Guiliang Hao; Yue Sun; Ai Zhang; Qin Wu; Zipu Li; Silin Pan

    doi:10.1101/2020.02.29.20027698 Date: 2020-03-03 Source: medRxiv

    Background: With the ongoing outbreak of Coronavirus Disease MESHD 2019 (COVID-19), infected MESHD patients within and beyond the epidemic area, Wuhan, China, showed different epidemiological and clinical characteristics. There is a paucity of data concerning coinfection with other common respiratory pathogens in COVID-19 patients outside of Wuhan. Methods: We conducted a double-centre study recruiting 68 patients with severe acute respiratory coronavirus 2 (SARS-CoV-2) infection MESHD infection confirmed TRANS by nucleic acid testing in Qingdao and Wuhan from January 17 to February 16, 2020. Indirect immunofluorescence was performed to detect the specific IgM antibody SERO against common respiratory pathogens in collected acute phase serum SERO. Results: Of the 68 patients with SARS-CoV-2 infection MESHD, 30 (44.12%) were from Qingdao. The median age TRANS of Qingdao and Wuhan patients were 50 (IQR: 37-59) and 31 (IQR: 28-38) years, respectively, and the majority of patients were female TRANS in Qingdao (60.00%) and Wuhan (55.26%). Among COVID-19 patients in Qingdao, 24 (80.00%) of them had IgM antibodies SERO against at least one respiratory pathogen, whereas only one (2.63%) of the patients in Wuhan had positive results for serum SERO IgM antibody SERO detection (P<0.0001). The most common respiratory pathogens detected in Qingdao COVID-19 patients were influenza virus A (60.00%) and influenza virus B (53.33%), followed by mycoplasma pneumoniae HP (23.33%) and legionella pneumophila MESHD (20.00%). While the pattern for coinfection in patients with community-acquired pneumonia HP pneumonia MESHD in Qingdao was quite different, with a positive rate of only 20.90%. Interpretation: We reported a large proportion of COVID-19 patients with coinfection of seasonal respiratory pathogens in Qingdao, northeast China, which differed greatly from the patients in Wuhan, central China. Precautions are needed when dealing with COVID-19 patients beyond the epidemic centre who have coinfection with other respiratory pathogens. We highly recommend adding SARS-CoV-2 to routine diagnostic testing in capable hospitals to prevent misdetection of the virus.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.